DeepMed Research

Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Bevacizumab

First Posted Date: 2009-10-20

Last Posted Date: 2024-07-30

Lead Sponsor: Columbia University

Target Recruit Count: 12

Registration Number: NCT00998166

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
North Shore University Hospital, Lake Success, New York, United States

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Phase 1

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Temsirolimus
Drug: Cisplatin
Drug: Erlotinib

First Posted Date: 2009-10-20

Last Posted Date: 2017-12-13

Lead Sponsor: Columbia University

Target Recruit Count: 9

Registration Number: NCT00998036

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)

Phase 2

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine, Docetaxel, Capecitabine

First Posted Date: 2009-10-16

Last Posted Date: 2016-07-25

Lead Sponsor: Columbia University

Target Recruit Count: 46

Registration Number: NCT00996333

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

Phase 1

Completed

Conditions: Hepatocellular Cancer

Interventions: Drug: Sorafenib

First Posted Date: 2009-10-16

Last Posted Date: 2015-08-10

Lead Sponsor: Columbia University

Target Recruit Count: 14

Registration Number: NCT00997022

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Bevacizumab
Drug: Erlotinib
Drug: Prednisone

First Posted Date: 2009-10-16

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 4

Registration Number: NCT00996502

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

Phase 2

Conditions: Mesothelioma

Interventions: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)

First Posted Date: 2009-10-16

Last Posted Date: 2011-10-31

Lead Sponsor: Columbia University

Target Recruit Count: 29

Registration Number: NCT00996385

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Family Cardiac Caregiver Investigation to Evaluate Outcomes

Completed

Conditions: Heart Diseases
Cardiovascular Diseases

First Posted Date: 2009-10-07

Last Posted Date: 2024-06-04

Lead Sponsor: Columbia University

Target Recruit Count: 4500

Registration Number: NCT00990548

Locations: 🇺🇸
Columbia University Medical Center/New York-Presbyterian Hosptial, New York, New York, United States

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: CoQ10
Other: CoQ10 Placebo
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2009-09-14

Last Posted Date: 2022-10-17

Lead Sponsor: Columbia University

Target Recruit Count: 7

Registration Number: NCT00976131

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science

Recruiting

Conditions: Congenital Diaphragmatic Hernia

First Posted Date: 2009-07-31

Last Posted Date: 2025-05-02

Lead Sponsor: Columbia University

Target Recruit Count: 3000

Registration Number: NCT00950118

Locations: 🇺🇸
Rush Hospital, Chicago, Illinois, United States
🇺🇸
University of Michigan/ CS Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
Washington University Medical Center/ St. Louis Children's Hospital, Saint Louis, Missouri, United States

and more 11 locations

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

Phase 3

Terminated

Conditions: Heart Failure

Interventions: Drug: LOVAZA (Omega-3)
Drug: Placebo

First Posted Date: 2009-07-23

Last Posted Date: 2016-05-25

Lead Sponsor: Columbia University

Target Recruit Count: 58

Registration Number: NCT00944229

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy